Cannabis Market in United States
Legal Status
Federally illegal; legal in 24+ states
Market Size
$30B+ (legal sales)
Region
North America
Market Overview
The United States is the largest cannabis market in the world by revenue, generating over $30 billion in legal sales annually across more than two dozen states that have legalized adult-use cannabis. However, cannabis remains a Schedule I controlled substance under federal law, creating a uniquely complex regulatory environment that shapes every aspect of the industry. This federal-state conflict is the defining characteristic of the US cannabis market and directly impacts how companies operate, raise capital, pay taxes, and access banking services.
The market is dominated by Multi-State Operators (MSOs) — vertically integrated companies that hold cultivation, processing, and retail licenses across multiple states. Because there is no federal license, companies must obtain separate state-level approvals for each market they enter. Major MSOs like Curaleaf, Green Thumb Industries, Trulieve, and Verano operate in 10 or more states and have built billion-dollar enterprises despite the federal prohibition. These companies trade primarily on OTC Markets since major US exchanges like NASDAQ and NYSE generally prohibit listing companies that directly handle federally illegal substances.
Section 280E of the Internal Revenue Code is one of the most significant financial burdens on US cannabis companies. This provision prevents businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, resulting in effective tax rates of 60-80% for many cannabis operators. The potential rescheduling of cannabis from Schedule I to Schedule III would eliminate 280E's applicability, which analysts estimate could increase industry profitability by 25-40% overnight. Rescheduling discussions have been active since 2023, with the DEA reviewing an HHS recommendation to move cannabis to Schedule III.
State-by-state legalization continues to expand the total addressable market. Key recent additions include Ohio, which approved adult-use in 2023, and states like Florida and Pennsylvania that are considering recreational legalization. Each new state represents both an expansion opportunity for existing MSOs and a potential catalyst for stock prices. The patchwork nature of state regulations — with varying license caps, vertical integration requirements, and social equity provisions — creates a market where local knowledge and regulatory expertise are significant competitive advantages.
Key Facts
- ▸Cannabis is legal for adult use in 24+ states and medical use in 38+ states, but remains federally illegal as a Schedule I substance.
- ▸Section 280E of the IRS code prevents cannabis companies from deducting standard business expenses, creating effective tax rates of 60-80%.
- ▸The US legal cannabis market generates over $30 billion in annual sales, with estimates projecting $50B+ by 2028.
- ▸Most US cannabis stocks (MSOs) trade on OTC Markets rather than major exchanges due to federal prohibition.
- ▸The SAFE Banking Act and potential rescheduling to Schedule III are the two most significant pending federal policy changes.
Cannabis Companies in United States
58 publicly traded cannabis companies headquartered in United States.
| Ticker | Name | Sector | Price | Change | Market Cap |
|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals | Biotech | $178.55 | -1.66% | $10.99B |
| SMG | Scotts Miracle-Gro | Ancillary | $60.96 | +0.96% | $3.54B |
| CURLF | Curaleaf Holdings | MSO | $2.36 | +2.83% | $1.80B |
| TPB | Turning Point Brands | Ancillary | $90.62 | +0.69% | $1.73B |
| GTBIF | Green Thumb Industries | MSO | $6.56 | +7.01% | $1.54B |
| IIPR | Innovative Industrial Properties | REIT | $52.66 | -2.34% | $1.48B |
| TCNNF | Trulieve Cannabis | MSO | $6.40 | +4.92% | $1.22B |
| MSOS | AdvisorShares Pure US Cannabis ETF | ETF | $3.82 | +1.33% | $764.3M |
| GLASF | Glass House Brands | MSO | $7.50 | -2.72% | $608.3M |
| VRNOF | Verano Holdings | MSO | $1.26 | -8.70% | $457.6M |
| KERN | Akerna Corp | Ancillary | $6.27 | +24.64% | $376.3M |
| NLCP | NewLake Capital Partners | REIT | $15.43 | -1.09% | $370.3M |
| CRLBF | Cresco Labs | MSO | $0.97 | -0.27% | $346.1M |
| PLNHF | Planet 13 Holdings | MSO | $0.91 | +5.21% | $295.8M |
| LFLY | Leafly Holdings | Ancillary | $135.50 | +17.98% | $271.0M |
| TSNDF | TerrAscend Corp | MSO | $0.68 | +0.37% | $261.4M |
| REFI | Chicago Atlantic Real Estate Finance | REIT | $12.09 | +0.33% | $254.9M |
| CCHWF | Columbia Care | MSO | $1.14 | -4.20% | $232.6M |
| GDNSF | Vireo Growth (Goodness Growth) | MSO | $0.44 | -1.12% | $182.2M |
| MJ | ETFMG Alternative Harvest ETF | ETF | $24.79 | +0.74% | $123.1M |
| CWBHF | Charlotte's Web Holdings | CBD | $0.62 | -0.22% | $99.3M |
| JUSHF | Jushi Holdings | MSO | $0.49 | -0.26% | $96.4M |
| AGFY | Agrify Corp | Ancillary | $47.12 | +4.71% | $94.2M |
| CNBS | Amplify Seymour Cannabis ETF | ETF | $23.50 | +1.95% | $77.3M |
| MAPS | WM Technology (Weedmaps) | Ancillary | $0.68 | -7.27% | $73.0M |
| FORA | Forian Inc | Ancillary | $2.05 | -0.97% | $63.7M |
| GRWG | GrowGeneration | Ancillary | $1.06 | -2.75% | $63.4M |
| AFCG | AFC Gamma (Advanced Flower Capital) | REIT | $2.63 | +0.38% | $61.9M |
| AAWH | Ascend Wellness Holdings | MSO | $0.49 | -0.89% | $47.0M |
| GRAMF | TPCO Holding (The Parent Company) | Ancillary | $0.16 | -12.99% | $45.7M |
| VEXTF | Vext Science | MSO | $0.19 | 0.00% | $34.2M |
| ZYNE | Zynerba Pharmaceuticals | Biotech | $1.30 | +3.17% | $33.8M |
| CXXIF | C21 Investments | MSO | $0.28 | +3.61% | $33.5M |
| THCX | Cannabis ETF | ETF | $16.60 | -0.26% | $33.2M |
| YOLO | AdvisorShares Pure Cannabis ETF | ETF | $2.83 | -4.88% | $33.1M |
| MRMD | MariMed Inc | MSO | $0.08 | +8.14% | $32.3M |
| ETST | Earth Science Tech | MSO | $0.11 | -5.17% | $32.2M |
| ITHUF | iAnthus Capital Holdings | MSO | $0.00 | -11.82% | $26.1M |
| CNTMF | Fluent Inc | MSO | $0.04 | -3.85% | $23.0M |
| TOKE | Cambria Cannabis ETF | ETF | $5.42 | 0.00% | $16.0M |
| CBSTF | The Cannabist Company | MSO | $0.03 | +4.29% | $14.6M |
| UNRV | Unrivaled Brands | MSO | $0.75 | 0.00% | $8.3M |
| WEED | Roundhill Cannabis ETF | ETF | $16.36 | +0.15% | $7.8M |
| YCBD | cbdMD Inc | CBD | $0.71 | -0.75% | $7.5M |
| CVSI | CV Sciences | CBD | $0.04 | -12.42% | $6.5M |
| HYFM | Hydrofarm Holdings | Ancillary | $1.19 | -6.30% | $5.6M |
| GNLN | Greenlane Holdings | Ancillary | $0.82 | -1.84% | $4.1M |
| BUDZ | Weed Inc | MSO | $0.03 | +9.83% | $3.8M |
| VIBEF | Vibe Growth | MSO | $0.03 | 0.00% | $2.8M |
| TGIFF | 1933 Industries | MSO | $0.01 | +10.42% | $2.6M |
| XXII | 22nd Century Group | Biotech | $3.88 | +1.97% | $2.0M |
| AYRWF | Ayr Wellness | MSO | $0.02 | -8.57% | $1.9M |
| CBDNF | CBD Global Sciences | CBD | $0.04 | +16.39% | $1.8M |
| CANB | Canbiola Inc | MSO | $0.02 | 0.00% | $1.4M |
| LVRLF | CordovaCann | MSO | $0.01 | 0.00% | $1.1M |
| ACRHF | Acreage Holdings | MSO | $0.00 | -4.76% | $323.6K |
| GCAN | Greater Cannabis Company | MSO | $0.12 | -36.11% | $103.5K |
| PNXP | Pineapple Express Cannabis | MSO | $0.00 | +111.11% | $94.2K |
Investment Considerations
The US market offers the largest revenue opportunity in global cannabis but comes with unique structural challenges. MSOs trade at significant valuation discounts to Canadian LPs despite having stronger fundamentals, largely due to federal illegality, OTC-only trading, and 280E taxation. Catalysts include federal rescheduling (which would eliminate 280E), the SAFE Banking Act (which would improve banking access), and continued state-level legalization. Investors should focus on companies with strong balance sheets, positive or near-positive free cash flow, and dominant positions in limited-license states. The OTC listing constraint means lower liquidity and limited institutional participation — but this also means potential upside if uplisting to major exchanges becomes possible.
Risk Factors
Federal enforcement risk remains theoretical but non-zero. 280E taxation severely impacts profitability and cash flow. OTC trading limits liquidity and institutional investment. State-by-state expansion is capital-intensive and regulatory approvals are uncertain. Oversupply in mature markets like Colorado and Oregon has compressed margins. The illicit market still commands roughly 60-70% of total US cannabis sales, competing directly on price. Share dilution has been significant across the sector as companies raise capital through equity offerings.
Frequently Asked Questions
Is cannabis legal in the United States?▼
Cannabis is legal for adult recreational use in 24+ states and for medical use in 38+ states, but it remains federally illegal as a Schedule I controlled substance. This federal-state conflict creates unique challenges for cannabis companies operating in legal states.
Why do US cannabis stocks trade on OTC Markets?▼
US cannabis companies that directly handle the plant (MSOs) trade on OTC Markets because major exchanges like NASDAQ and NYSE, regulated by the SEC, generally prohibit companies involved in federally illegal activities from listing. Canadian LPs can list on NASDAQ because cannabis is federally legal in Canada.
What is Section 280E and how does it affect cannabis stocks?▼
Section 280E is a provision of the US tax code that prevents businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. This results in effective tax rates of 60-80% for cannabis companies. Rescheduling cannabis to Schedule III would eliminate this burden.
What would cannabis rescheduling mean for US cannabis stocks?▼
Rescheduling cannabis from Schedule I to Schedule III would eliminate Section 280E taxation, potentially increasing industry profitability by 25-40%. It could also open the door to major exchange listings, institutional investment, and improved banking access, all of which would be significant stock catalysts.
Explore Other Markets
Continue Exploring
Disclaimer: The information on this page is provided for educational and informational purposes only and does not constitute financial, legal, or investment advice. Cannabis laws and regulations vary by jurisdiction and are subject to change. Market size estimates are approximations based on publicly available data. Always consult with qualified professionals before making investment decisions. Past performance does not guarantee future results. Cannabismarketcap does not recommend the purchase or sale of any security.